Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 26;11:510–519. doi: 10.1016/j.dadm.2019.05.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 1 — Differences in plasma Aβ measures by diagnosis and amyloid positivity. Plasma Aβ measures of free Aβ42-to-Aβ40 ratio (FP42:FP40; A) and total Aβ42 to Aβ40 ratio (TP42:TP40; B) were significantly different by diagnostic group, primarily driven by reduced values in patients with AD (both P < .05). When combined across groups, Aβ-positive individuals showed no significant difference from Aβ-negative individuals in FP42:FP40 (P > .05; C), but significantly lower TP42:TP40 (P = .031; D). Finally, Aβ-positive patients with AD had significantly lower FP42:FP40 (overall P value = .093; E) and TP42:TP40 (overall P value = .001; F) relative to Aβ-negative CNs (pairwise P ≤ .05 after Bonferroni correction). Results are shown as adjusted mean for each group with standard error as the error bars. Abbreviations: Aβ, amyloid beta; CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer's disease.